NEW YORK (GenomeWeb News) – FlexGen today announced that it has closed a round of private equity financing with an undisclosed amount of funding coming from BioGeneration Ventures and Crédit Agricole Private Equity.

The amount of the funding was in the several million euros, according to FlexGen CEO Fred Dom.

The firm, based in Leiden, The Netherlands, intends to use the money to speed up development and global commercialization of its FlexArrayer for producing custom microarrays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.